2026 Q1 -tulosraportti
8 päivää sitten
‧57 min
1,49 EUR/osake
Irtoamispäivä 22.5.
3,86%Tuotto/v
Tarjoustasot
Xetra
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 4.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 5.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 5.8.2025 | ||
Vuosittainen yhtiökokous 2025 22.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5.5.From Wall street journal: Fresenius Medical Care (FME) – Q1 2026: Shares fall on weak US dialysis volumes What happened today? The share fell more than 3% on Tuesday, after the world's largest dialysis provider reported weaker same-market treatment growth in the US for the first quarter. The figures Same-market treatment growth in the US deteriorated to 0,4% from 0,2% in the previous quarter – thus missing the company's full-year guidance for flat growth. Revenue landed at €4,61 billion, down 5,5% year-over-year but up 4% organically, and beat analysts' consensus of €4,59 billion. Adjusted operating income rose 2% to €467 million, in line with expectations of €466 million, and lifted the adjusted operating margin to 10,1% from 9,4% the previous year. Adjusted net income of €251 million was below analysts' average estimate of €256 million. Guidance confirmed – but without enthusiasm The company confirmed its full-year guidance for 2026 for broadly flat revenue growth and adjusted operating income in a range from a small decrease to a small increase (mid-single digit). The structural challenge The problem is not new. Underlying volumes are the central problem – same-market treatment growth in the US fell 0,2% in Q4 2025, which underlines that the latest profit improvement is driven more by pricing and efficiencies than by patient growth. Citi analysts point out that the market will likely remain focused on the low US treatment volumes as a prerequisite for any meaningful acceleration in earnings. Strategy and cost savings CEO Helen Giza has reacted with divestments and an expanded savings program, where the target has been raised to €1,2 billion in savings by the end of 2027, compared to the previous €1,05 billion. The company combines the weaker 2026-guidance with a dividend increase of 3% to €1,49 per share and an accelerated share buyback program of €1 billion – a signal of increased focus on capital returns.
31.1.2022 · Muokattu31.1.2022 · Muokattuhttps://dntv.dn.no/m/giDR19NE/nyrene-pavirkes-av-long-covid-det-vil-ha-stor-betydning-for-mange-det-neste-tiaret-eller-lenger
31.1.2022 · Muokattu31.1.2022 · MuokattuGoldman Sachs has today reaffirmed its "Conviction Buy List" rating for Fresenius Medical Care (target € 97). FMC will profit from the US tax reform. I like both FMC and her mother (Fresenius SE). Those are good, shareholder friendly, defensive health stocks with fine track records and growth opportunities many years ahead. The Novo Nordisk & Novozymes of Germany 😉 Both companies report Q4 on feb. 27th, and you may consider to buy some shares even before those numbers, taking advantage of current share prices. A risk worth calculating, IMO.
31.1.2022 · Muokattu31.1.2022 · MuokattuFresenius Medical Care reports fourth quarter and full year 2015 results - Targets for 2015 achieved: revenue + 11% constant currency, net income ,2 +2% - 3% dividend increase to be proposed at the Annual General Meeting - Excellent organic growth and positive operating earnings development in North America - Strong organic growth dynamic in Care Coordination activities, still in investment mode - International performance furthermore impacted by currency fluctuations - Result pushed by Global Efficiency Program and lower costs for healthcare supplies http://www.bloomberg.com/press-releases/2016-02-24/dgap-news-fresenius-medical-care-reports-fourth-quarter-and-full-year-2015-results
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
8 päivää sitten
‧57 min
1,49 EUR/osake
Irtoamispäivä 22.5.
3,86%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5.5.From Wall street journal: Fresenius Medical Care (FME) – Q1 2026: Shares fall on weak US dialysis volumes What happened today? The share fell more than 3% on Tuesday, after the world's largest dialysis provider reported weaker same-market treatment growth in the US for the first quarter. The figures Same-market treatment growth in the US deteriorated to 0,4% from 0,2% in the previous quarter – thus missing the company's full-year guidance for flat growth. Revenue landed at €4,61 billion, down 5,5% year-over-year but up 4% organically, and beat analysts' consensus of €4,59 billion. Adjusted operating income rose 2% to €467 million, in line with expectations of €466 million, and lifted the adjusted operating margin to 10,1% from 9,4% the previous year. Adjusted net income of €251 million was below analysts' average estimate of €256 million. Guidance confirmed – but without enthusiasm The company confirmed its full-year guidance for 2026 for broadly flat revenue growth and adjusted operating income in a range from a small decrease to a small increase (mid-single digit). The structural challenge The problem is not new. Underlying volumes are the central problem – same-market treatment growth in the US fell 0,2% in Q4 2025, which underlines that the latest profit improvement is driven more by pricing and efficiencies than by patient growth. Citi analysts point out that the market will likely remain focused on the low US treatment volumes as a prerequisite for any meaningful acceleration in earnings. Strategy and cost savings CEO Helen Giza has reacted with divestments and an expanded savings program, where the target has been raised to €1,2 billion in savings by the end of 2027, compared to the previous €1,05 billion. The company combines the weaker 2026-guidance with a dividend increase of 3% to €1,49 per share and an accelerated share buyback program of €1 billion – a signal of increased focus on capital returns.
- 31.1.2022 · Muokattu31.1.2022 · Muokattuhttps://dntv.dn.no/m/giDR19NE/nyrene-pavirkes-av-long-covid-det-vil-ha-stor-betydning-for-mange-det-neste-tiaret-eller-lenger
- 31.1.2022 · Muokattu31.1.2022 · MuokattuGoldman Sachs has today reaffirmed its "Conviction Buy List" rating for Fresenius Medical Care (target € 97). FMC will profit from the US tax reform. I like both FMC and her mother (Fresenius SE). Those are good, shareholder friendly, defensive health stocks with fine track records and growth opportunities many years ahead. The Novo Nordisk & Novozymes of Germany 😉 Both companies report Q4 on feb. 27th, and you may consider to buy some shares even before those numbers, taking advantage of current share prices. A risk worth calculating, IMO.
- 31.1.2022 · Muokattu31.1.2022 · MuokattuFresenius Medical Care reports fourth quarter and full year 2015 results - Targets for 2015 achieved: revenue + 11% constant currency, net income ,2 +2% - 3% dividend increase to be proposed at the Annual General Meeting - Excellent organic growth and positive operating earnings development in North America - Strong organic growth dynamic in Care Coordination activities, still in investment mode - International performance furthermore impacted by currency fluctuations - Result pushed by Global Efficiency Program and lower costs for healthcare supplies http://www.bloomberg.com/press-releases/2016-02-24/dgap-news-fresenius-medical-care-reports-fourth-quarter-and-full-year-2015-results
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Xetra
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 4.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 5.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 5.8.2025 | ||
Vuosittainen yhtiökokous 2025 22.5.2025 |
2026 Q1 -tulosraportti
8 päivää sitten
‧57 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 4.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 5.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 5.8.2025 | ||
Vuosittainen yhtiökokous 2025 22.5.2025 |
1,49 EUR/osake
Irtoamispäivä 22.5.
3,86%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5.5.From Wall street journal: Fresenius Medical Care (FME) – Q1 2026: Shares fall on weak US dialysis volumes What happened today? The share fell more than 3% on Tuesday, after the world's largest dialysis provider reported weaker same-market treatment growth in the US for the first quarter. The figures Same-market treatment growth in the US deteriorated to 0,4% from 0,2% in the previous quarter – thus missing the company's full-year guidance for flat growth. Revenue landed at €4,61 billion, down 5,5% year-over-year but up 4% organically, and beat analysts' consensus of €4,59 billion. Adjusted operating income rose 2% to €467 million, in line with expectations of €466 million, and lifted the adjusted operating margin to 10,1% from 9,4% the previous year. Adjusted net income of €251 million was below analysts' average estimate of €256 million. Guidance confirmed – but without enthusiasm The company confirmed its full-year guidance for 2026 for broadly flat revenue growth and adjusted operating income in a range from a small decrease to a small increase (mid-single digit). The structural challenge The problem is not new. Underlying volumes are the central problem – same-market treatment growth in the US fell 0,2% in Q4 2025, which underlines that the latest profit improvement is driven more by pricing and efficiencies than by patient growth. Citi analysts point out that the market will likely remain focused on the low US treatment volumes as a prerequisite for any meaningful acceleration in earnings. Strategy and cost savings CEO Helen Giza has reacted with divestments and an expanded savings program, where the target has been raised to €1,2 billion in savings by the end of 2027, compared to the previous €1,05 billion. The company combines the weaker 2026-guidance with a dividend increase of 3% to €1,49 per share and an accelerated share buyback program of €1 billion – a signal of increased focus on capital returns.
- 31.1.2022 · Muokattu31.1.2022 · Muokattuhttps://dntv.dn.no/m/giDR19NE/nyrene-pavirkes-av-long-covid-det-vil-ha-stor-betydning-for-mange-det-neste-tiaret-eller-lenger
- 31.1.2022 · Muokattu31.1.2022 · MuokattuGoldman Sachs has today reaffirmed its "Conviction Buy List" rating for Fresenius Medical Care (target € 97). FMC will profit from the US tax reform. I like both FMC and her mother (Fresenius SE). Those are good, shareholder friendly, defensive health stocks with fine track records and growth opportunities many years ahead. The Novo Nordisk & Novozymes of Germany 😉 Both companies report Q4 on feb. 27th, and you may consider to buy some shares even before those numbers, taking advantage of current share prices. A risk worth calculating, IMO.
- 31.1.2022 · Muokattu31.1.2022 · MuokattuFresenius Medical Care reports fourth quarter and full year 2015 results - Targets for 2015 achieved: revenue + 11% constant currency, net income ,2 +2% - 3% dividend increase to be proposed at the Annual General Meeting - Excellent organic growth and positive operating earnings development in North America - Strong organic growth dynamic in Care Coordination activities, still in investment mode - International performance furthermore impacted by currency fluctuations - Result pushed by Global Efficiency Program and lower costs for healthcare supplies http://www.bloomberg.com/press-releases/2016-02-24/dgap-news-fresenius-medical-care-reports-fourth-quarter-and-full-year-2015-results
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Xetra
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt